Cargando…

Circulating miR-31 as an effective biomarker for detection and prognosis of human cancer: a meta-analysis

PURPOSE: Circulating miR-31 was found to be associated with cancers detection and prognosis. The present meta-analysis aimed to explore the effect of circulating miR-31 on cancer detection and prognosis. METHOD: The studies were accessed using multiple databases. RevMan5.3, Meta-DiSc 1.4, and STATA1...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Yingjun, Chen, Yunfang, Lin, Jinbo, Liu, Yi, Luo, Kai, Cao, Yong, Wang, Tieqiang, Jin, Hongwei, Su, Zhan, Wu, Haolin, Chen, Xiaoliang, Cheng, Jinquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438681/
https://www.ncbi.nlm.nih.gov/pubmed/28404921
http://dx.doi.org/10.18632/oncotarget.15638
_version_ 1783237819054948352
author Ma, Yingjun
Chen, Yunfang
Lin, Jinbo
Liu, Yi
Luo, Kai
Cao, Yong
Wang, Tieqiang
Jin, Hongwei
Su, Zhan
Wu, Haolin
Chen, Xiaoliang
Cheng, Jinquan
author_facet Ma, Yingjun
Chen, Yunfang
Lin, Jinbo
Liu, Yi
Luo, Kai
Cao, Yong
Wang, Tieqiang
Jin, Hongwei
Su, Zhan
Wu, Haolin
Chen, Xiaoliang
Cheng, Jinquan
author_sort Ma, Yingjun
collection PubMed
description PURPOSE: Circulating miR-31 was found to be associated with cancers detection and prognosis. The present meta-analysis aimed to explore the effect of circulating miR-31 on cancer detection and prognosis. METHOD: The studies were accessed using multiple databases. RevMan5.3, Meta-DiSc 1.4, and STATA14.0 were used to estimate the pooled effects, heterogeneity among studies, and publication bias. RESULTS: A total of 14 studies with 1397 cancer patients and 1039 controls were included. For the 12 prognostic tests, the adjusted pooled-AUC was 0.79 (95% CI: 0.73-0.86) as the pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odd ratio (DOR) from 10 tests was 0.79 (95% CI: 0.76-0.82), 0.79 (95% CI: 0.76-0.82), 3.81 (95% CI: 2.90-5.01), 0.26 (95% CI: 0.20-0.35), and 16.81 (95% CI: 9.67-29.25), respectively. For the 5 prognosis analyses, the pooled HR (hazard ratio) of overall survival (OS) was 1.55 (95% CI 1.30-1.86) for high versus low circulating miR-31 expression. However, high expression of circulating miR-31 did not significantly increase the risk of poor differentiation (pooled OR=1.39, 95% CI: 0.56-3.47) and LNM (pooled OR=3.46, 95% CI: 0.96-12.42) in lung cancer. CONCLUSION: Circulating miR-31 is an effective biomarker and could be used as a component of miRs signature for cancer detection and prognosis surveillance.
format Online
Article
Text
id pubmed-5438681
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-54386812017-05-24 Circulating miR-31 as an effective biomarker for detection and prognosis of human cancer: a meta-analysis Ma, Yingjun Chen, Yunfang Lin, Jinbo Liu, Yi Luo, Kai Cao, Yong Wang, Tieqiang Jin, Hongwei Su, Zhan Wu, Haolin Chen, Xiaoliang Cheng, Jinquan Oncotarget Research Paper PURPOSE: Circulating miR-31 was found to be associated with cancers detection and prognosis. The present meta-analysis aimed to explore the effect of circulating miR-31 on cancer detection and prognosis. METHOD: The studies were accessed using multiple databases. RevMan5.3, Meta-DiSc 1.4, and STATA14.0 were used to estimate the pooled effects, heterogeneity among studies, and publication bias. RESULTS: A total of 14 studies with 1397 cancer patients and 1039 controls were included. For the 12 prognostic tests, the adjusted pooled-AUC was 0.79 (95% CI: 0.73-0.86) as the pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odd ratio (DOR) from 10 tests was 0.79 (95% CI: 0.76-0.82), 0.79 (95% CI: 0.76-0.82), 3.81 (95% CI: 2.90-5.01), 0.26 (95% CI: 0.20-0.35), and 16.81 (95% CI: 9.67-29.25), respectively. For the 5 prognosis analyses, the pooled HR (hazard ratio) of overall survival (OS) was 1.55 (95% CI 1.30-1.86) for high versus low circulating miR-31 expression. However, high expression of circulating miR-31 did not significantly increase the risk of poor differentiation (pooled OR=1.39, 95% CI: 0.56-3.47) and LNM (pooled OR=3.46, 95% CI: 0.96-12.42) in lung cancer. CONCLUSION: Circulating miR-31 is an effective biomarker and could be used as a component of miRs signature for cancer detection and prognosis surveillance. Impact Journals LLC 2017-02-23 /pmc/articles/PMC5438681/ /pubmed/28404921 http://dx.doi.org/10.18632/oncotarget.15638 Text en Copyright: © 2017 Ma et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Ma, Yingjun
Chen, Yunfang
Lin, Jinbo
Liu, Yi
Luo, Kai
Cao, Yong
Wang, Tieqiang
Jin, Hongwei
Su, Zhan
Wu, Haolin
Chen, Xiaoliang
Cheng, Jinquan
Circulating miR-31 as an effective biomarker for detection and prognosis of human cancer: a meta-analysis
title Circulating miR-31 as an effective biomarker for detection and prognosis of human cancer: a meta-analysis
title_full Circulating miR-31 as an effective biomarker for detection and prognosis of human cancer: a meta-analysis
title_fullStr Circulating miR-31 as an effective biomarker for detection and prognosis of human cancer: a meta-analysis
title_full_unstemmed Circulating miR-31 as an effective biomarker for detection and prognosis of human cancer: a meta-analysis
title_short Circulating miR-31 as an effective biomarker for detection and prognosis of human cancer: a meta-analysis
title_sort circulating mir-31 as an effective biomarker for detection and prognosis of human cancer: a meta-analysis
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438681/
https://www.ncbi.nlm.nih.gov/pubmed/28404921
http://dx.doi.org/10.18632/oncotarget.15638
work_keys_str_mv AT mayingjun circulatingmir31asaneffectivebiomarkerfordetectionandprognosisofhumancancerametaanalysis
AT chenyunfang circulatingmir31asaneffectivebiomarkerfordetectionandprognosisofhumancancerametaanalysis
AT linjinbo circulatingmir31asaneffectivebiomarkerfordetectionandprognosisofhumancancerametaanalysis
AT liuyi circulatingmir31asaneffectivebiomarkerfordetectionandprognosisofhumancancerametaanalysis
AT luokai circulatingmir31asaneffectivebiomarkerfordetectionandprognosisofhumancancerametaanalysis
AT caoyong circulatingmir31asaneffectivebiomarkerfordetectionandprognosisofhumancancerametaanalysis
AT wangtieqiang circulatingmir31asaneffectivebiomarkerfordetectionandprognosisofhumancancerametaanalysis
AT jinhongwei circulatingmir31asaneffectivebiomarkerfordetectionandprognosisofhumancancerametaanalysis
AT suzhan circulatingmir31asaneffectivebiomarkerfordetectionandprognosisofhumancancerametaanalysis
AT wuhaolin circulatingmir31asaneffectivebiomarkerfordetectionandprognosisofhumancancerametaanalysis
AT chenxiaoliang circulatingmir31asaneffectivebiomarkerfordetectionandprognosisofhumancancerametaanalysis
AT chengjinquan circulatingmir31asaneffectivebiomarkerfordetectionandprognosisofhumancancerametaanalysis